
Congrats to Andreas and Yue for the best paper award! #eau24 sciencedirect.com/science/articl…

English
Günter Niegisch
117 posts







In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment. Full trial results: nej.md/49ViJEe


































